Organon & Co. (NYSE:OGN) Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC raised its position in Organon & Co. (NYSE:OGN) by 2,103,633.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,112 shares of the company’s stock after acquiring an additional 63,109 shares during the quarter. Acadian Asset Management LLC’s holdings in Organon & Co. were worth $1,306,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Atomi Financial Group Inc. grew its position in Organon & Co. by 1.8% in the 1st quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock valued at $618,000 after acquiring an additional 593 shares in the last quarter. Bill Few Associates Inc. grew its position in shares of Organon & Co. by 5.4% during the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after buying an additional 621 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Organon & Co. by 19.2% during the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock worth $84,000 after buying an additional 649 shares in the last quarter. Benedetti & Gucer Inc. grew its position in shares of Organon & Co. by 3.4% during the first quarter. Benedetti & Gucer Inc. now owns 20,245 shares of the company’s stock worth $381,000 after buying an additional 670 shares in the last quarter. Finally, Signaturefd LLC grew its position in shares of Organon & Co. by 6.6% during the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

OGN stock opened at $20.47 on Monday. The business has a 50 day moving average price of $21.02 and a 200 day moving average price of $20.03. The stock has a market cap of $5.26 billion, a price-to-earnings ratio of 5.00, a PEG ratio of 0.89 and a beta of 0.85. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.04. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.31 earnings per share. Equities research analysts anticipate that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 5.47%. The ex-dividend date of this dividend was Friday, August 16th. Organon & Co.’s dividend payout ratio is currently 27.38%.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price objective for the stock from $18.00 to $20.00 in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Organon & Co. presently has an average rating of “Hold” and an average target price of $22.17.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.